{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:06:16Z","timestamp":1782929176122,"version":"3.54.5"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020912","name":"King Faisal University","doi-asserted-by":"publisher","award":["KFU253819"],"award-info":[{"award-number":["KFU253819"]}],"id":[{"id":"10.13039\/501100020912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD) represents a significant microvascular complication associated with type 2 diabetes mellitus (T2DM), markedly elevating the risk of kidney failure, cardiovascular events, and premature mortality. Despite advancements in therapeutic management, such as renin\u2013angiotensin\u2013aldosterone system (RAAS) blockade and sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors, residual risk remains significant. Finerenone, a novel nonsteroidal and selective mineralocorticoid receptor antagonist (MRA), has demonstrated substantial cardiorenal benefits in clinical trials; however, real-world data, especially from Saudi Arabia, remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This single-center, retrospective cohort study. All adult patients (\u226518 years) who received finerenone as part of routine clinical care were eligible if they met either of the following criteria: (1) documented diabetic kidney disease (DKD) based on KDIGO-aligned clinical criteria, including diabetes mellitus with chronic kidney disease manifested by albuminuria\/proteinuria and\/or reduced eGFR; (2) and\/or a urine protein-to-creatinine ratio (uPCR) &gt;0.3 mg\/mg. Longitudinal changes in uPCR, eGFR, and serum potassium were analyzed using linear mixed-effects models adjusted for relevant clinical covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 75 patients prescribed finerenone were screened, of whom 67 met the inclusion criteria. The median age was 63 years, and 53.7% were female. Comorbidities were highly prevalent, including diabetes mellitus (89.6%), hypertension (97.0%), dyslipidemia (92.5%), heart failure (56.8%), and coronary artery disease (40.3%). A significant effect of time on uPCR was observed (F[3,193] = 3.457; P\u2009=\u20090.018), with a mean reduction of 0.464 mg\/mg after six months (95% CI, \u22120.895 to \u22120.034; P\u2009=\u20090.027). The estimated eGFR slope after finerenone initiation was \u22121.08 mL\/min\/1.73 m\u00b2 per month (95% CI \u22121.74 to \u22120.41; P\u2009=\u20090.002), corresponding to an annualized decline of approximately \u221212.9 mL\/min\/1.73 m\u00b2 per year. Serum potassium increased modestly at early follow-up points (F[5,245] = 4.008; P\u2009=\u20090.002), rising by +0.209,\u2009+\u20090.256, and +0.286 mmol\/L at the first three readings (P\u2009=\u20090.029, 0.005, and 0.006, respectively), then plateaued thereafter (P\u2009&gt;\u20090.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Finerenone use among DKD patients in Saudi Arabia was associated with significant reductions in proteinuria, an early decline in eGFR that requires cautious interpretation, and an overall favorable safety profile. These real-world findings align with results from pivotal clinical trials and support the incorporation of finerenone into standard DKD management. Future multicenter prospective studies are warranted to confirm these outcomes and evaluate long-term cardiorenal benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0352861","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:28:12Z","timestamp":1782926892000},"page":"e0352861","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of Finerenone in patients with diabetic kidney disease in Saudi Arabia"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8472-3043","authenticated-orcid":true,"given":"Mohamed A.","family":"Albekery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3346-1223","authenticated-orcid":true,"given":"Ibrahim S.","family":"Alhomoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid A.","family":"Alamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3611-0529","authenticated-orcid":true,"given":"Ahmed A.","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8522-3480","authenticated-orcid":true,"given":"Abdulmohsen E.","family":"Al Mulhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2152-2710","authenticated-orcid":true,"given":"Ahmed E.","family":"Alnaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5819-1972","authenticated-orcid":true,"given":"Fahad M.","family":"Almulhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1856-2835","authenticated-orcid":true,"given":"Abdulrahman S.","family":"Almulhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2777-0926","authenticated-orcid":true,"given":"Saleh A.","family":"Al Makhaytah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema H.","family":"Aldawsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthana","family":"Al Sahlawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6347-4743","authenticated-orcid":true,"given":"Mohammed Y.","family":"Almulhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"3","key":"pone.0352861.ref001","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2004","article-title":"Diabetes mellitus, the fastest growing global public health concern: early detection should be focused","volume":"7","author":"MJ Hossain","year":"2024","journal-title":"Health Sci Rep"},{"issue":"10397","key":"pone.0352861.ref002","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"pone.0352861.ref003","doi-asserted-by":"crossref","first-page":"1501690","DOI":"10.3389\/fendo.2024.1501690","article-title":"Global burden of type 2 diabetes mellitus from 1990 to 2021, with projections of prevalence to 2044: a systematic analysis across SDI levels for the global burden of disease study 2021","volume":"15","author":"K-J He","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"pone.0352861.ref004","doi-asserted-by":"crossref","first-page":"2413922","DOI":"10.1080\/07853890.2024.2413922","article-title":"Characteristics and risk factors associated with developing prediabetes in Saudi Arabia","volume":"56","author":"AM Tourkmani","year":"2024","journal-title":"Ann Med"},{"issue":"12","key":"pone.0352861.ref005","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"IH de Boer","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"pone.0352861.ref006","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"M Afkarian","year":"2016","journal-title":"JAMA"},{"issue":"9854","key":"pone.0352861.ref007","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"CS Fox","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"pone.0352861.ref008","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-Kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"CE Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"9","key":"pone.0352861.ref009","doi-asserted-by":"crossref","first-page":"100873","DOI":"10.1016\/j.xkme.2024.100873","article-title":"Healthcare costs across diabetic kidney disease stages: a veterans affairs study","volume":"6","author":"K Kim","year":"2024","journal-title":"Kidney Med"},{"issue":"1","key":"pone.0352861.ref010","first-page":"80","article-title":"Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population","volume":"29","author":"H Chung","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"pone.0352861.ref011","article-title":"Prevalence of microalbuminuria and cardiovascular risk factors in patients with diabetes mellitus Type-II in Al-Khobar, Kingdom of Saudi Arabia","volume":"14","author":"N-A Jatoi","year":"2022","journal-title":"Cureus"},{"key":"pone.0352861.ref012","doi-asserted-by":"crossref","first-page":"1580645","DOI":"10.3389\/fmed.2025.1580645","article-title":"Finerenone in diabetic kidney disease: a new frontier for slowing disease progression","volume":"12","author":"IS Alhomoud","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"pone.0352861.ref013","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"pone.0352861.ref014","article-title":"Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems","author":"IS Alhomoud","year":"2025","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"pone.0352861.ref015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"V Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0352861.ref016","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"J Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"pone.0352861.ref017","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"M Epstein","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"pone.0352861.ref018","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/ph17040418","article-title":"Finerenone: from the mechanism of action to clinical use in kidney disease","volume":"17","author":"N Piko","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"23","key":"pone.0352861.ref019","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"GL Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0352861.ref020","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with Finerenone in kidney disease and type 2 diabetes","volume":"385","author":"B Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0352861.ref021","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"R Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"pone.0352861.ref022","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease","volume":"47","author":"Y Zheng","year":"2022","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"pone.0352861.ref023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/2633559X231171861","article-title":"Understanding the role of Finerenone among current treatment options for diabetic kidney disease","volume":"11","author":"V Zbyrak","year":"2023","journal-title":"ADCES Pract"},{"issue":"6","key":"pone.0352861.ref024","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"R Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"pone.0352861.ref025","doi-asserted-by":"crossref","first-page":"100294","DOI":"10.1016\/j.metop.2024.100294","article-title":"Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease","volume":"22","author":"A Mima","year":"2024","journal-title":"Metabol Open"},{"key":"pone.0352861.ref026","doi-asserted-by":"crossref","first-page":"100251","DOI":"10.1016\/j.metop.2023.100251","article-title":"Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL\/min\/1.73 m2","volume":"19","author":"A Mima","year":"2023","journal-title":"Metabolism Open"},{"issue":"17","key":"pone.0352861.ref027","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.3390\/jcm13175107","article-title":"Early clinical experience of Finerenone in people with chronic kidney disease and type 2 diabetes in Japan-a multi-cohort study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform","volume":"13","author":"A Sato","year":"2024","journal-title":"J Clin Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:28:17Z","timestamp":1782926897000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352861"}},"subtitle":[],"editor":[{"given":"Anukul","family":"Ghimire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352861","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}